Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Changing your injection day safely Life changes
This approach is particularly beneficial for: Individuals with a BMI under 27 who want to prevent gradual weight gain Those looking to reduce cravings and improve portion control Patients maintaining weight loss after a larger reduction People with a healthy BMI but struggling with stubborn fat Unlike full-dose Semaglutide treatments, microdosing offers more subtle appetite regulation , helping individuals avoid overeating and weight fluctuations without significant fat loss
Its programs, which include disease-specific education for diabetes, cancer and HIV, have been licensed by hundreds of health care systems, community organizations and other groups around the world